Please upgrade your browser.
Cancer patients who receive a combination of low-dose interleukin-2 and retinoic acid after conventional therapy seem to live longer than those who don't get the combination.
Maria Teresa Fahy discusses her poster.
Scientists at Washington University School of Medicine in St. Louis are using powerful DNA sequencing technology not only to identify mutations at the root of a patient's tumor -- considered key to personalizing cancer treatment -- but to map the genetic evolution of disease and monitor response to treatment.
We are building the world's largest community for families dealing with a child's encounter with Wilms tumor, a pediatric form of kidney cancer. All are welcome to join! This effort is supported by members of the International Kidney Cancer Congress (#IKCC on Twitter).
The treatment, an antibody that blocks a "do not eat" signal normally displayed on tumor cells, coaxes the immune system to destroy the cancer cells.
In 1975, 2,953 people were diagnosed with kidney cancer in Britain. Latest figures show there were 9,042 cases in 2009, up from 8,848 in 2008.
Patients with papillary renal cell carcinoma, the second most common kidney cancer subtype, face a low risk of tumour recurrence and cancer-related death after surgery. Those are the key findings of a multi-centre study of nearly 600 patients published in the April issue of the urology journal BJUI.
The Stanford team examined cancer cells removed from patients with a variety of types of solid tumors. They found that CD47 studded the membranes of almost all of the cancer cells in their sample, suggesting that it is a molecule common to all cancers.
Opinion: These pre-clinical findings could provide the thesis for a potential positive outcome in the current Phase 1 study "A Phase I Study of Ridaforolimus and Vorinostat in Patients With Advanced Renal Cell Carcinoma (RCC)...
|Powered by NeonCRM|